Venetoclax

2:13
The future prospects of adapting genomics to clinical practice
Prof Wee Joo Chng
10:40
Predictors in the novel therapy era
John Seymour et al.
19:15
Highlights from iwCLL 2019: MRD and novel therapies:
Lydia Scarfo et al.
14:54
Assessing the role of CAR-T in CLL
David Maloney et al.
17:22
Varying efficacies of combination and monotherapies in CLL
Alessandra Tedeschi et al.
4:03
Updates from the ERIC: a focus on MRD-guided approaches
Paolo Ghia
1:53
VENICE I: MRD response with venetoclax in R/R CLL
Arnon Kater
2:27
Real-world evidence of venetoclax vs ibrutinib vs idelalisib
Toby Eyre
4:20
Waldenström’s Macroglobulinemia venetoclax therapy
Jorge Castillo
1:12
Frontline, fixed-duration venetoclax/obinutuzumab: PFS and MRD data from CLL14
Barbara Eichhorst
3:02
Tailored treatment strategies for CLL
Danielle Brander
3:58
Mantle cell lymphoma update: changing times & latest news
Simon Rule
2:30
ViPOR regimen for R/R B-cell lymphoma
Wyndham Wilson
2:00
Venetoclax plus rituximab or obinutuzumab in CLL after alloHCT
Othman Al-Sawaf
2:39
Does chemotherapy still have a role in the treatment of Waldenström’s?
Steven Treon
3:35
Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Sasanka Handunnetti
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals